Update on the management of BCOR::CCNB3 sarcoma
Japanese Journal of Clinical Oncology · 07.10.2025 · 55 (10) · 1097-1104
DOI: 10.1093/jjco/hyaf111 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 13.07.2025. Verfasst von Jungo Imanishi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan. Hauptthemen laut MEDLINE: Repressor Proteins, Proto-Oncogene Proteins, Sarcoma, Cyclin B. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
BCOR::CCNB3 sarcoma is a rare sarcoma defined by the BCOR::CCNB3 fusion gene. It predominantly affects males under 20, with a slight predominance of bone origin. Initially grouped as ‘Ewing-like,’ it is now a distinct entity, a major part of ‘sarcoma with BCOR genetic alterations.’ Incidence is low, estimated at under 10 annual cases in Japan. Radiologically, it can mimic other high-grade sarcomas, with variable lytic or sclerotic bone lesions and nonspecific soft tissue findings. By contrast, it sometimes appears well-defined and benign-like. Pathologically, the detection of BCOR::CCNB3 fusion is key to diagnosis. Histology varies from small round cells to spindle cells, showing CD99, BCOR, Cyclin D1, and SATB2 positivity, with CCNB3 differentiating it from BCOR-ITD. Molecular testing confirms the diagnosis. Treatment involves wide resection and chemotherapy, with the Ewing sarcoma protocol often chosen. Approximately 20% are metastatic at diagnosis, and local recurrence after surgery occurs in as high as ⁓20% of BCOR::CCNB3 sarcomas. The relatively high local recurrence rate is probably because of the infiltrative growth. Complete response to neoadjuvant chemotherapy may indicate a better prognosis. Less frequent metastasis at diagnosis indicates that this sarcoma is less aggressive than Ewing sarcoma. Five-year overall survival is ⁓75%, but the prognosis of non-resectable or metastatic cases is worse. Further research is crucial for tailored treatment. Due to the tumor's super-rarity, collaborative, multi-institutional studies are essential, allowing for robust clinical trials and outcome analyses. Long-term follow-up studies are also necessary to assess late effects and survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan.
- Department of Pathology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan.
- Department of Radiology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan.
- Department of Orthopaedic Surgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
ORCID-Profile: Jungo Imanishi, Yoshinao Kikuchi, Hiroshi Kobayashi
Zitieren
APA
Imanishi, J., Sato, K., Kikuchi, Y., Yamamoto, A., Watabe, S., Matsuyama, T., Sato, C., Kobayashi, H., & Kawano, H. (2025). Update on the management of BCOR::CCNB3 sarcoma. Japanese Journal of Clinical Oncology, 55(10), 1097-1104. https://doi.org/10.1093/jjco/hyaf111
Vancouver
Imanishi J, Sato K, Kikuchi Y, Yamamoto A, Watabe S, Matsuyama T, et al. Update on the management of BCOR::CCNB3 sarcoma. Japanese Journal of Clinical Oncology. 2025;55(10):1097-1104. doi:10.1093/jjco/hyaf111
BibTeX
@article{Imanishi2025,
author = {Imanishi, Jungo and Sato, Kenji and Kikuchi, Yoshinao and Yamamoto, Asako and Watabe, Shiori and Matsuyama, Taisuke and Sato, Chiaki and Kobayashi, Hiroshi and Kawano, Hirotaka},
title = {Update on the management of BCOR::CCNB3 sarcoma},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
volume = {55},
number = {10},
pages = {1097--1104},
doi = {10.1093/jjco/hyaf111}
}
EUVIMED